Therapeutic Recommendations for Nephroblastoma

NCT ID: NCT04423484

Last Updated: 2025-10-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-07-01

Study Completion Date

2027-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is based on results form 2 previous studies carried out by the GFAOP. The aim of this study is to evaluate the capacity of units to follow the recommendations in the protocol.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is based on results form 2 previous studies carried out by the GFAOP. This study aims to evaluate the capacity of units to follow the recommendations in the protocol. It will look mainly at treatment compliance and outcome for the children treated. The study will also evaluate the improvement in treatment compliance and reporting. This work will help the group to evaluate future needs in participating units and help us adapt treatment programmes to local conditions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nephroblastoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Children with Nephroblastoma

All children coming into the participating units with suspected Nephroblastoma.

Data collection

Intervention Type OTHER

Clinical stage, treatment given and observations of toxicity if any, outcome following treatment and follow up.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Data collection

Clinical stage, treatment given and observations of toxicity if any, outcome following treatment and follow up.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Unilateral Nephroblastoma Tumor Not previously treated The general health of the child will permit treatment.

.

Exclusion Criteria

Bilateral Nephroblastoma tumor Previously treated Disease too advanced Doubt concerning the diagnosis Treatment Refusal
Minimum Eligible Age

6 Months

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

French Africa Pediatric Oncology Group

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Fatou Binetou Ms DIAGNE AKONDE, Dr

Role: PRINCIPAL_INVESTIGATOR

French Africa Pediatric Oncology Group

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre Hospitalier Universitaire Pédiatrique Charles De Gaulle

Ouagadougou, , Burkina Faso

Site Status RECRUITING

CHU de Treichville à ABIDJAN

Abidjan, Abidjan Autonomous District, Côte d’Ivoire

Site Status RECRUITING

CUK (Cliniques Universitaires de Kinshasa)

Kinshasa, , Democratic Republic of the Congo

Site Status RECRUITING

Cliniques Universitaires de Lubumbashi (CUL)

Lubumbashi, , Democratic Republic of the Congo

Site Status RECRUITING

HJRA, Hôpital universitaire Joseph Ravoahangy Andrianavalona

Antananarivo, , Madagascar

Site Status RECRUITING

CHU Gabriel Touré (HGT)

Bamako, , Mali

Site Status RECRUITING

Hôpital Aristide Le Dantec, Avenue Pasteur, BP 3001

Dakar, Dakar, Senegal

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Burkina Faso Côte d’Ivoire Democratic Republic of the Congo Madagascar Mali Senegal

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

BRENDA Ms MALLON, MSC

Role: CONTACT

0033142115411

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sonia Ms Kaboret, Dr

Role: primary

[email protected]

Role: backup

Line Guei COUITCHERE, MD

Role: primary

Aléine BUDIONGO, DR

Role: primary

+(243)99 81 53 133.

Robert LUKAMBA, DR

Role: primary

00(243) 814024633

Mbola Mr RAKOTOMAHEFA, Dr

Role: primary

Boubacar TOGO, PROFESSEUR

Role: primary

+223 66 74 29 04

DIAGNE AKONDE Fatou-Binetou, Dr

Role: primary

00(221)77 637 40 63

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GFANEPHRO2020

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.